Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress T Lammers, F Kiessling, WE Hennink, G Storm Journal of controlled release 161 (2), 175-187, 2012 | 1546 | 2012 |
Tumor targeting via EPR: Strategies to enhance patient responses SK Golombek, JN May, B Theek, L Appold, N Drude, F Kiessling, ... Advanced drug delivery reviews 130, 17-38, 2018 | 1119 | 2018 |
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective JI Hare, T Lammers, MB Ashford, S Puri, G Storm, ST Barry Advanced drug delivery reviews 108, 25-38, 2017 | 1089 | 2017 |
Theranostic nanomedicine T Lammers, S Aime, WE Hennink, G Storm, F Kiessling Accounts of chemical research 44 (10), 1029-1038, 2011 | 983 | 2011 |
Smart cancer nanomedicine R van der Meel, E Sulheim, Y Shi, F Kiessling, WJM Mulder, T Lammers Nature nanotechnology 14 (11), 1007-1017, 2019 | 919 | 2019 |
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications SM Dadfar, K Roemhild, NI Drude, S von Stillfried, R Knüchel, F Kiessling, ... Advanced drug delivery reviews 138, 302-325, 2019 | 917 | 2019 |
Tumour-targeted nanomedicines: principles and practice T Lammers, WE Hennink, G Storm British journal of cancer 99 (3), 392-397, 2008 | 705 | 2008 |
The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy Y Shi, R van der Meel, X Chen, T Lammers Theranostics 10 (17), 7921, 2020 | 559 | 2020 |
Applications of nanoparticles for diagnosis and therapy of cancer SC Baetke, T Lammers, F Kiessling The British journal of radiology 88 (1054), 20150207, 2015 | 514 | 2015 |
Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation M Talelli, M Barz, CJF Rijcken, F Kiessling, WE Hennink, T Lammers Nano today 10 (1), 93-117, 2015 | 510 | 2015 |
PLGA-based nanoparticles in cancer treatment S Rezvantalab, NI Drude, MK Moraveji, N Güvener, EK Koons, Y Shi, ... Frontiers in pharmacology 9, 1260, 2018 | 472 | 2018 |
Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects S Kunjachan, J Ehling, G Storm, F Kiessling, T Lammers Chemical reviews 115 (19), 10907-10937, 2015 | 468 | 2015 |
Nanotheranostics and image-guided drug delivery: current concepts and future directions T Lammers, F Kiessling, WE Hennink, G Storm Molecular pharmaceutics 7 (6), 1899-1912, 2010 | 467 | 2010 |
Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner C Zhang, M Jugold, EC Woenne, T Lammers, B Morgenstern, MM Mueller, ... Cancer research 67 (4), 1555-1562, 2007 | 451 | 2007 |
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications LY Rizzo, B Theek, G Storm, F Kiessling, T Lammers Current opinion in biotechnology 24 (6), 1159-1166, 2013 | 384 | 2013 |
Passive versus active tumor targeting using RGD-and NGR-modified polymeric nanomedicines S Kunjachan, R Pola, F Gremse, B Theek, J Ehling, D Moeckel, ... Nano letters 14 (2), 972-981, 2014 | 355 | 2014 |
Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics F Kiessling, S Fokong, P Koczera, W Lederle, T Lammers Journal of nuclear medicine 53 (3), 345-348, 2012 | 354 | 2012 |
Targeting iron metabolism in drug discovery and delivery BJ Crielaard, T Lammers, S Rivella Nature Reviews Drug Discovery 16 (6), 400-423, 2017 | 324 | 2017 |
Combining nanomedicine and immunotherapy Y Shi, T Lammers Accounts of chemical research 52 (6), 1543-1554, 2019 | 317 | 2019 |
CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis J Ehling, M Bartneck, X Wei, F Gremse, V Fech, D Möckel, C Baeck, ... Gut 63 (12), 1960-1971, 2014 | 304 | 2014 |